Circulating levels of adiponectin, leptin, and tumour necrosis factor in hypertension

Annals of Medicine

Volumn 41, Issue 4, 2009, Pages 291-300

  Patel, Jeetesh V ^a   Lim, Hoong S ^a   Dubb, Kiran ^a   Hughes, Elizabeth A ^a   Lip, Gregory Y H ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

Adipocytokines; Blood pressure; Cardiovascular disease; Metabolism

Indexed keywords

ADIPONECTIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEPTIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; CROSS-SECTIONAL STUDY; MIDDLE AGED; OBESITY; REGRESSION ANALYSIS; RISK FACTOR;

ADIPONECTIN; AGED; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; LEPTIN; MALE; MIDDLE AGED; OBESITY; REGRESSION ANALYSIS; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67649710357     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.1080/07853890802672839     Document Type: Article

References (26)

1. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774
2. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838
3. Patel JV, Lim HS, Gunarathne A, Tracey I, Durrington PN, Hughes EA, et al. Ethnic differences in myocardial infarction in patients with hypertension: effects of diabetes mellitus. QJM. 2008;101:231-236
4. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113: 1213-1225
5. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. National Heart, Lung, and Blood Institute; American Heart Association. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433-438
6. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287: 356-359
7. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716
8. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-689
9. Alberti KGMM, Zimmet P, Shaw J. for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome*a new worldwide definition. Lancet. 2005;366: 1059-1062 (Pubitemid 41338752)
10. Patel JV, Lim HS, Hughes EA, Lip GY. Adiponectin and hypertension: a putative link between adipocyte function and atherosclerotic risk? J Hum Hypertens. 2007;21:1.
11. Wassink AM, Olijhoek JK, Visseren FL. The metabolic syndrome: metabolic changes with vascular consequences. Eur J Clin Invest. 2007;37:8-17.
12. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79-83.
13. Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens. 2003;6:72-75
14. Mahmud A, Feely J. Adiponectin and arterial stiffness. Am J Hypertens. 2005;18:1543-1548
15. Mallamaci F, Zoccali C, Cuzzola F, Tripepi G, Cutrupi S, Parlongo S, et al. Adiponectin in essential hypertension. J Nephrol. 2002;15:507-511
16. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension. 2003;42:76-81.
17. Banks WA. The many lives of leptin. Peptides. 2004;25: 331-338
18. Quilliot D, Bohme P, Zannad F, Ziegler O. Sympathetic-leptin relationship in obesity: effect of weight loss. Metabolism. 2008;57:555-562
19. Takahashi N, Waelput W, Guisez Y. Leptin is an endogenous protective protein against the toxicity exerted by tumour necrosis factor. J Exp Med. 1999;189:207-212
20. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. ASCOT Steering Committee, Anglo-Scandinavian Cardiac Outcomes Trial. Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol. J Hum Hypertens. 2001;15 Suppl 1:S11-2.
21. Agata J, Masuda A, Takada M, Higashiura K, Murakami H, Miyazaki Y, et al. High plasma immunoreactive leptin level in essential hypertension. Am J Hypertens. 1997;10:1171.
22. Ouchi N, Ohishi M, Kihara S, Funahashi T, Nakamura T, Nagaretani H, et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension. 2003;42:231-234
23. Cigolini M, Targher G, Bergamo Andreis IA, Tonoli M, Agostino G, et al. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol. 1996;16:368-374 (Pubitemid 26084311)
24. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20:1595-1599
25. Lim HS, Tayebjee MH, Tan KT, Patel JV, Macfadyen RJ, Lip GYH. Severity differences and relation to coronary artery disease serum adiponectin in coronary heart disease: Heart. 2005;91:1605-1606
26. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003;163:427-436